Drug Profile
Research programme: Clostridium difficile infections vaccine - CaroGen Corporation
Latest Information Update: 01 Nov 2023
Price :
$50
*
At a glance
- Originator CaroGen
- Developer CaroGen; University of Connecticut
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Clostridium difficile infections
Most Recent Events
- 01 Nov 2023 Discontinued - Preclinical for Clostridium difficile infections in USA (unspecified route)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Clostridium-difficile-infections in USA
- 03 Aug 2016 Preclinical trials in Clostridium difficile infections in USA (unspecified route) (Carogen Corporation website, August 2016)